{"type":"trials","record":{"id":41899,"source_id":"clinicaltrials-gov","external_id":"NCT06699914","title":"A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)","brief_summary":"A retrospective, observational, single-arm, non-randomized cohort study of ocular treatment in nAMD patients in Japan who had records of at least 12 months of follow-up after their first brolucizumab intravitreal injection. Patients who had records of at least 12 months of visits after the first brolucizumab injection (index date) were identified during the index period and were recruited during the data collection/recruitment period.","overall_status":"Completed","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Novartis Pharmaceuticals","enrollment":438,"countries":["United States"],"start_date":"2022-09-06","completion_date":"2023-12-01","last_update_date":"2024-11-21","source_url":"https://clinicaltrials.gov/study/NCT06699914","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"PHEASANT","age_range":"50 Years","comparator":null,"organization":"Novartis","interventions":[],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of Patients With Absence of Intra-retinal Fluid (IRF) and Absence of Subretinal Fluid (SRF) at Month 12 — Month…","Number of Patients With Absence of IRF and Absence of SRF at Month 3, 6, 9, and 18 — Month 3, 6, 9, and 18","Demographic: Age — Baseline","Demographic: Number of Patients per Age Category — Baseline","Demographic: Gender — Baseline","Number of Patients per Clinical Characteristic — Baseline","Clinical Characteristic: Time Between Diagnosis and First Brolucizumab Injection — Baseline","Clinical Characteristic: Time Between Diagnosis and First Treatment — Baseline","Clinical Characteristic: Central Subfield Thickness (CSFT) — Baseline","Clinical Characteristic: Visual Acuity (VA) — Baseline","Clinical Characteristic: VA in Each Subtype — Baseline","Number of Patients by Type of Previous Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment — Up to 12 months…","Last Injection Interval of Anti-VEGF Treatment Before Switching — Up to 12 months pre-baseline","Number of Injections in the Last 6 Months Before Switching to Brolucizumab — Up to 6 months pre-baseline","Number of Injections in the Last 6 Months After Switching to Brolucizumab — Up to 6 months post-baseline","Number of Injections in the Last 12 Months Before Switching to Brolucizumab — Up to 12 months pre-baseline","Number of Injections in the Last 12 Months After Switching to Brolucizumab — Up to 12 months post-baseline","Number of Patients With Absence of Subretinal Fluid (SRF) — Month 3, 6, 9, 12 and 18","Number of Patients with Absence of Intra-retinal Fluid (IRF) — Month 3, 6, 9, 12, and 18","Number of Patients with Absence of Sub-retinal Pigment Epithelium (sub-RPE) Fluid — Month 3, 6, 9, 12, and 18"],"design_description":null,"source_has_results":false},"controlled_terms":["Neovascular Age-Related Macular Degeneration"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06699914","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-09-06 to 2023-12-01","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.889Z","intervention":[],"participants":438,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of Patients With Absence of Intra-retinal Fluid (IRF) and Absence of Subretinal Fluid (SRF) at Month 12 — Month…","Number of Patients With Absence of IRF and Absence of SRF at Month 3, 6, 9, and 18 — Month 3, 6, 9, and 18","Demographic: Age — Baseline","Demographic: Number of Patients per Age Category — Baseline","Demographic: Gender — Baseline","Number of Patients per Clinical Characteristic — Baseline","Clinical Characteristic: Time Between Diagnosis and First Brolucizumab Injection — Baseline","Clinical Characteristic: Time Between Diagnosis and First Treatment — Baseline","Clinical Characteristic: Central Subfield Thickness (CSFT) — Baseline","Clinical Characteristic: Visual Acuity (VA) — Baseline","Clinical Characteristic: VA in Each Subtype — Baseline","Number of Patients by Type of Previous Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment — Up to 12 months…","Last Injection Interval of Anti-VEGF Treatment Before Switching — Up to 12 months pre-baseline","Number of Injections in the Last 6 Months Before Switching to Brolucizumab — Up to 6 months pre-baseline","Number of Injections in the Last 6 Months After Switching to Brolucizumab — Up to 6 months post-baseline","Number of Injections in the Last 12 Months Before Switching to Brolucizumab — Up to 12 months pre-baseline","Number of Injections in the Last 12 Months After Switching to Brolucizumab — Up to 12 months post-baseline","Number of Patients With Absence of Subretinal Fluid (SRF) — Month 3, 6, 9, 12 and 18","Number of Patients with Absence of Intra-retinal Fluid (IRF) — Month 3, 6, 9, 12, and 18","Number of Patients with Absence of Sub-retinal Pigment Epithelium (sub-RPE) Fluid — Month 3, 6, 9, 12, and 18"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41899","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}